Jim Cramer says health care is the 'cold' hedge your AI-heavy portfolio is missing — and shares 4 stocks to consider

Jim Cramer argues that health care is the 'cold' hedge missing from AI-heavy portfolios after the 10 largest S&P 500 companies came to represent roughly 40% of the index. He highlights CVS Health, Cardinal Health, Johnson & Johnson, and UnitedHealth Group as defensive alternatives to the crowded AI trade. The piece is commentary rather than a catalyst, but it may reinforce rotation interest into lagging health care names.

Analysis

This is less a broad call on health care than a rotation thesis driven by positioning. When leadership narrows this far, the first money typically comes out of crowded factor winners, not into the new group immediately, so the setup favors a defensive basket as a volatility hedge rather than a pure relative-value bet on secular outperformance. The immediate second-order effect is pressure on passive and factor products: if the AI cohort wobbles, mechanical de-risking can create a fast, indiscriminate bid for low-beta, cash-generative defensives like managed care, distribution, and branded pharma.

The interesting nuance is that the four names are not the same trade. UNH is the highest-quality balance sheet/earnings compounder, but it is also the least “cheap” defensively; it works best as a market hedge if growth-multiple compression hits the index. JNJ is the cleanest refuge from sentiment shocks, but the upside is mostly multiple support rather than earnings acceleration. CVS and CAH are more catalyst-driven: they need operational execution and sentiment repair, which means they can outperform sharply over 3-6 months if investors rotate into neglected cash flow, but they also carry higher idiosyncratic risk if pricing pressure or reimbursement noise resurfaces.

The consensus risk is assuming this is simply a mean-reversion trade back into laggards. If the AI-led market breadth remains tight, health care can stay cheap for longer because investors will keep paying for earnings acceleration, not stability. The real catalyst is not health care improving on its own; it is a drawdown or air pocket in tech that forces allocators to rebalance. In that sense, the trade has better convexity as a hedge than as a standalone alpha source.

From a timing standpoint, this is a days-to-weeks protection trade, with the strongest payoff if tech breadth deteriorates before quarter-end flows normalize. On a 6-12 month horizon, the most attractive setup is a pair expressing quality defensives versus expensive AI leaders, because the relative valuation gap is now large enough that even modest multiple compression in tech can fund a meaningful rerating in health care.

Key Decisions for Investors

• Buy UNH and JNJ as a 6-12 month defensive sleeve; use 5-8% portfolio weights combined, targeting low-to-mid single-digit upside with materially lower drawdown if AI leadership breaks.
• Initiate a pair trade: long UNH / short a basket of high-multiple AI winners for 1-3 months; target 1.5-2.0x downside capture if index breadth rolls over, with the short leg acting as the primary catalyst.
• Use CVS as the higher-beta recovery idea only on weakness over the next 2-4 weeks; smaller sizing is appropriate because the risk/reward is more catalyst-dependent and less purely defensive.
• Prefer CAH as a relative-value long versus broader health care peers if you want operating leverage to a risk-off rotation; upside is best over 3-6 months if investors pay for neglected cash flow.
• If Nasdaq breadth deteriorates for two consecutive weeks, add to the health-care hedge basket and trim AI exposure; this is where the sector can rerate fastest due to positioning, not fundamentals.